Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.
2.

Cetuximab: a review of its use in squamous cell carcinoma of the head and neck.

Frampton JE.

Drugs. 2010 Oct 22;70(15):1987-2010. doi: 10.2165/11205010-000000000-00000. Review.

PMID:
20883055
3.

New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).

Agulnik M.

Med Oncol. 2012 Dec;29(4):2481-91. doi: 10.1007/s12032-012-0159-2. Epub 2012 Jan 18. Review.

4.

Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications.

Langer CJ.

Cancer. 2008 Jun 15;112(12):2635-45. doi: 10.1002/cncr.23521. Review.

5.

Cetuximab in the treatment of head and neck cancer.

Bernier J.

Expert Rev Anticancer Ther. 2006 Nov;6(11):1539-52. Review.

PMID:
17134359
6.
7.

Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer.

López-Albaitero A, Ferris RL.

Arch Otolaryngol Head Neck Surg. 2007 Dec;133(12):1277-81.

PMID:
18086972
8.

IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.

Herbst RS, Hong WK.

Semin Oncol. 2002 Oct;29(5 Suppl 14):18-30. Review.

PMID:
12422310
9.

The role of inhibitors of the epidermal growth factor in management of head and neck cancer.

Brockstein B, Lacouture M, Agulnik M.

J Natl Compr Canc Netw. 2008 Aug;6(7):696-706. Review.

PMID:
18691458
10.

Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.

Martinelli E, De Palma R, Orditura M, De Vita F, Ciardiello F.

Clin Exp Immunol. 2009 Oct;158(1):1-9. doi: 10.1111/j.1365-2249.2009.03992.x. Review.

11.

Cetuximab in squamous cell carcinoma of the head and neck.

Hitt R, Martín P, Hidalgo M.

Future Oncol. 2006 Aug;2(4):449-57. Review.

PMID:
16922611
12.

Epidermal growth factor receptor directed therapy in head and neck cancer.

Choong NW, Cohen EE.

Crit Rev Oncol Hematol. 2006 Jan;57(1):25-43. Epub 2005 Oct 3. Review.

PMID:
16207530
13.

[Immunotherapy of head and neck cancer. Identification of a novel mechanism for anti-EGFR mAb anti-tumor effects].

Hoffmann TK.

HNO. 2011 Mar;59(3):224-9. doi: 10.1007/s00106-010-2251-2. German.

PMID:
21424359
14.

Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab.

Moon C, Chae YK, Lee J.

Exp Biol Med (Maywood). 2010 Aug;235(8):907-20. doi: 10.1258/ebm.2009.009181. Epub 2010 Jun 18. Review.

PMID:
20562132
15.

Treatment of advanced head and neck cancer with cetuximab.

Merlano M, Garrone O.

Int J Biol Markers. 2007 Jan-Mar;22(1 Suppl 4):S71-6. Review.

PMID:
17520584
16.

Spotlight on cetuximab in squamous cell carcinoma of the head and neck.

Frampton JE.

BioDrugs. 2011 Apr 1;25(2):129-33. doi: 10.2165/11207030-000000000-00000.

PMID:
21443275
17.

Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer.

Wheeler RH, Spencer S, Buchsbaum D, Robert F.

Curr Opin Oncol. 1999 May;11(3):187-90. Review.

PMID:
10328593
18.

Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin.

Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, Iyer H, Arvind AS.

MAbs. 2009 Jan-Feb;1(1):41-8. Review.

19.

Advances in molecular diagnostics and therapeutics in head and neck cancer.

Chai RL, Grandis JR.

Curr Treat Options Oncol. 2006 Jan;7(1):3-11. Review.

PMID:
16343364
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk